INZY241220C5000
- 0.10
- +0.03+42.86%
Inozyme Pharma Newsroom
Inozyme Pharma to Participate in the Piper Sandler 36th Annual Healthcare Conference
Inozyme Pharma (NASDAQ:INZY) Has Debt But No Earnings; Should You Worry?
Here's Why Inozyme Pharma (INZY) Is Poised for a Turnaround After Losing -29.98% in 4 Weeks
Stifel Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $16
H.C. Wainwright Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $14
TD Cowen Maintains Inozyme Pharma(INZY.US) With Buy Rating
Promising Developments in Inozyme Pharma's INZ-701 Drive Buy Recommendation
Express News | Inozyme Pharma Inc : Wedbush Cuts Target Price to $12 From $15
Inozyme Pharma | 10-Q: Q3 2024 Earnings Report
Inozyme Pharma | 8-K: Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Express News | Inozyme Pharma: Cash, Cash Equivalents, and Short-Term Investments as of September 30, 2024, Expected to Fund Operations Into Q4 2025
Express News | Inozyme Pharma Inc: Interim Data From Energy 1, a Phase 1B Trial of Inz-701 in Infants With Enpp1 Deficiency, on Track for Q4 of 2024
Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Express News | Inozyme Pharma Q3 Net Income USD -24.6 Million
Press Release: Inozyme Pharma Reports Third Quarter 2024 Financial Results and Provides Business Highlights
Express News | Inozyme Pharma Q3 EPS USD -0.39
BofA Securities Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $13
Needham Maintains Inozyme Pharma(INZY.US) With Buy Rating, Maintains Target Price $23
Inozyme Pharma Price Target Maintained With a $23.00/Share by Needham
Analysts Offer Insights on Healthcare Companies: Dexcom (DXCM) and Inozyme Pharma (INZY)